Nanopore technology offers a relatively low cost per sample, making it an attractive option for rapid diagnostics and the detection of structural abnormalities, such as the PML::RARA fusion in APL patients, across a wide range of patient populations. The gene discussed is RARA; the disease is acute promyelocytic leukemia.